Vertex Amend its Collaboration with CRISPR Therapeutics for Development and Commercialization of CTX001 in SCD and Beta Thalassemia

Shots:

• CRISPR to receive $900M up front with an additional $200M milestone upon the regulatory approval of CTX001. Vertex will responsible for the global development, manufacturing, and commercialization of CTX001
• Vertex will be responsible for 60% of program costs and will receive 60% of profits from future sales of CTX001 globally, representing a 10% increase in program economics compared to the previous agreement
• CRISPR continues to support the development of CTX001 and will be responsible for 40% of costs and will receive the same proportion of profits

Click here to­ read full press release/ article | Ref: Vertex | Image: PJ Dionne